Identification of coexistence of DNA methylation and H3K27me3 specifically in cancer cells as a promising target for epigenetic therapy

Carcinogenesis

Volumn 36, Issue 2, 2014, Pages 192-201

  Takeshima, Hideyuki ^a   Wakabayashi, Mika ^a   Hattori, Naoko ^a   Yamashita, Satoshi ^a   Ushijima, Toshikazu ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ENTINOSTAT; HISTONE H3; HISTONE H3 LYSINE 27; LYSINE; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; 5 AZA 2' DEOXYCYTIDINE; ANTINEOPLASTIC AGENT; AZACITIDINE; BENZAMIDE DERIVATIVE; ENZYME INHIBITOR; EZH2 PROTEIN, HUMAN; GSK126; HISTONE; HISTONE DEACETYLASE INHIBITOR; INDOLE DERIVATIVE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-RELATED PROTEIN 1; MEMBRANE PROTEIN; POLYCOMB REPRESSIVE COMPLEX 2; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; SFRP1 PROTEIN, HUMAN; SIGNAL PEPTIDE; SOMATOMEDIN BINDING PROTEIN;

ARTICLE; BREAST CANCER CELL LINE; CANCER CELL; CANCER THERAPY; CELL GROWTH; DEMETHYLATION; DNA DETERMINATION; DNA METHYLATION; EPIGENETICS; EPITHELIUM CELL; GENE EXPRESSION; GENE ONTOLOGY; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; TARGET CELL; TRANSCRIPTION INITIATION SITE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HCT116 CELL LINE; MALE; MCF 7 CELL LINE; METABOLISM; MOUSE; NEOPLASMS; NUDE MOUSE; PROMOTER REGION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; BENZAMIDES; CELL PROLIFERATION; DNA METHYLATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HISTONE DEACETYLASE INHIBITORS; HISTONES; HUMANS; INDOLES; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MCF-7 CELLS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; POLYCOMB REPRESSIVE COMPLEX 2; PROMOTER REGIONS, GENETIC; PYRIDINES; PYRIDONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84926430579     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu238     Document Type: Article

References (50)

1. Jones, P.A. et al. (2007) The epigenomics of cancer. Cell, 128, 683-692.
2. Laird, P.W. et al. (1996) The role of DNA methylation in cancer genetic and epigenetics. Annu. Rev. Genet., 30, 441-464.
3. Issa, J.P. (2007) DNA methylation as a therapeutic target in cancer. Clin. Cancer Res., 13, 1634-1637.
4. Mund, C. et al. (2010) Epigenetic cancer therapy: Proof of concept and remaining challenges. Bioessays, 32, 949-957.
5. DeWoskin, V.A. et al. (2013) The epigenetics pipeline. Nat. Rev. Drug Discov., 12, 661-662.
6. Kantarjian, H. et al. (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer, 106, 1794-1803.
7. Silverman, L.R. et al. (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol., 20, 2429-2440.
8. New, M. et al. (2012) HDAC inhibitor-based therapies: can we interpret the code? Mol. Oncol., 6, 637-656.
9. Juergens, R.A. et al. (2011) Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov., 1, 598-607.
10. Daigle, S.R. et al. (2011) Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell, 20, 53-65.
11. Knutson, S.K. et al. (2013) Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2. Proc. Natl. Acad. Sci. USA, 110, 7922-7927.
12. Kubicek, S. et al. (2007) Reversal of H3K9me2 by a small-molecule inhibitor for the G9a histone methyltransferase. Mol. Cell, 25, 473-481.
13. McCabe, M.T. et al. (2012) EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature, 492, 108-112.
14. Qi, W. et al. (2012) Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc. Natl. Acad. Sci. USA, 109, 21360-21365.
15. Dammann, R. et al. (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet., 25, 315-319.
16. Merlo, A. et al. (1995) 5' CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1, 686-692.
17. Rice, J.C. et al. (2000) Transcriptional repression of BRCA1 by aberrant cytosine methylation, histone hypoacetylation and chromatin condensation of the BRCA1 promoter. Nucleic Acids Res., 28, 3233-3239.
18. Fujii, S. et al. (2008) Enhancer of zeste homolog 2 downregulates E-cadherin by mediating histone H3 methylation in gastric cancer cells. Cancer Sci., 99, 738-746.
19. Osada, H. et al. (2008) Roles of achaete-scute homologue 1 in DKK1 and E-cadherin repression and neuroendocrine differentiation in lung cancer. Cancer Res., 68, 1647-1655.
20. Kondo, Y. et al. (2008) Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat. Genet., 40, 741-750.
21. Kouzarides, T. (2007) Chromatin modifications and their function. Cell, 128, 693-705.
22. Smith, Z.D. et al. (2013) DNA methylation: roles in mammalian development. Nat. Rev. Genet., 14, 204-220.
23. Di Croce, L. et al. (2013) Transcriptional regulation by Polycomb group proteins. Nat. Struct. Mol. Biol., 20, 1147-1155.
24. Levin, H.L. et al. (2011) Dynamic interactions between transposable elements and their hosts. Nat. Rev. Genet., 12, 615-627.
25. Hahn, M.A. et al. (2008) Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res., 68, 10280-10289.
26. McCabe, M.T. et al. (2009) A multifactorial signature of DNA sequence and polycomb binding predicts aberrant CpG island methylation. Cancer Res., 69, 282-291.
27. Ohm, J.E. et al. (2007) A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet., 39, 237-242.
28. Schlesinger, Y. et al. (2007) Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet., 39, 232-236.
29. Takeshima, H. et al. (2009) The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. Genome Res., 19, 1974-1982.
30. Widschwendter, M. et al. (2007) Epigenetic stem cell signature in cancer. Nat. Genet., 39, 157-158.
31. Gal-Yam, E.N. et al. (2008) Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. Proc. Natl. Acad. Sci. USA, 105, 12979-12984.
32. Brinkman, A.B. et al. (2012) Sequential ChIP-bisulfite sequencing enables direct genome-scale investigation of chromatin and DNA methylation cross-talk. Genome Res., 22, 1128-1138.
33. Murphy, P.J. et al. (2013) Single-molecule analysis of combinatorial epigenomic states in normal and tumor cells. Proc. Natl. Acad. Sci. USA, 110, 7772-7777.
34. Gao, F. et al. (2014) Direct ChIP-bisulfite sequencing reveals a role of H3K27me3 mediating aberrant hypermethylation of promoter CpG islands in cancer cells. Genomics, 103, 204-210.
35. Kim, J.G. et al. (2013) Comprehensive DNA methylation and extensive mutation analyses reveal an association between the CpG island methylator phenotype and oncogenic mutations in gastric cancers. Cancer Lett., 330, 33-40.
36. Dennis, Jr. G. et al. (2003) DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol., 4, P 3.
37. Huang da, W. et al. (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc., 4, 44-57.
38. Suzuki, H. et al. (2002) A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet., 31, 141-149.
39. Ugolini, F. et al. (2001) WNT pathway and mammary carcinogenesis: loss of expression of candidate tumor suppressor gene SFRP1 in most invasive carcinomas except of the medullary type. Oncogene, 20, 5810-5817.
40. Wajapeyee, N. et al. (2008) Oncogenic BRAF induces senescence and apoptosis through pathways mediated by the secreted protein IGFBP7. Cell, 132, 363-374.
41. Statham, A.L. et al. (2012) Bisulfite sequencing of chromatin immunoprecipitated DNA (BisChIP-seq) directly informs methylation status of histone-modified DNA. Genome Res., 22, 1120-1127.
42. Filippakopoulos, P. et al. (2010) Selective inhibition of BET bromodomains. Nature, 468, 1067-1073.
43. Picaud, S. et al. (2013) RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc. Natl. Acad. Sci. USA, 110, 19754-19759.
44. Bernstein, B.E. et al. (2006) A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell, 125, 315-326.
45. Füllgrabe, J. et al. (2011) Histone onco-modifications. Oncogene, 30, 3391-3403.
46. Plass, C. et al. (2013) Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat. Rev. Genet., 14, 765-780.
47. Jones, S.E. et al. (2002) Secreted Frizzled-related proteins: searching for relationships and patterns. Bioessays, 24, 811-820.
48. Nojima, M. et al. (2007) Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene, 26, 4699-4713.
49. Bartke, T. et al. (2010) Nucleosome-interacting proteins regulated by DNA and histone methylation. Cell, 143, 470-484.
50. Carninci, P. et al. (2006) Genome-wide analysis of mammalian promoter architecture and evolution. Nat. Genet., 38, 626-635.